Eli Lilly Raises Guidance as Revenue Beat Overpowers EPS Miss

Eli Lilly (LLY), ranking 15th by market capitalization reported its fiscal 2026 Q2 earnings on Aug 04th, 2026.

The company delivered a significant beat on the top line, reporting revenue of $22.97 billion against consensus estimates of approximately $20.73 billion. This topline strength was accompanied by a notable upward revision in full-year guidance, with revenue projections lifted to $85.0–$87.0 billion. While non-GAAP EPS guidance was raised, the final reported figure missed initial expectations due to one-time charges, though the overall narrative remained constructive for long-term growth drivers.

Revenue

The total revenue of Eli Lilly increased by 47.7% to $22.97 billion in 2026 Q2, up from $15.56 billion in 2025 Q2. In detailing the specific segment revenue listed as follow: Mounjaro contributed $9.94 billion, Zepbound added $4.93 billion, Jaypirca generated $192 million, Ebglyss brought in $201 million, Kisunla recorded $167 million, Omvoh accounted for $102 million, Inluriyo reached $75 million, and Foundayo posted $98 million, culminating in the Total Revenue of $22.97 billion.

Earnings/Net Income

Eli Lilly's EPS rose 26.2% to $7.94 in 2026 Q2 from $6.29 in 2025 Q2, marking continued earnings growth. Meanwhile, the company's profitability strengthened with net income of $7.09 billion in 2026 Q2, marking 25.3% growth from $5.66 billion in 2025 Q2. Remarkably, in 2026 Q2, the company set a new record high for fiscal Q2 net income, the highest in over 20 years. The reported EPS performance indicates robust operational efficiency despite one-time charges.

Price Action

The stock price of Eli Lilly has edged down 0.15% during the latest trading day, has tumbled 8.60% during the most recent full trading week, and has tumbled 8.09% month-to-date.

Post Earnings Price Action Review

The latest LLY revenue-beat backtest works, but the setup is fragile. Using the most recent confirmed revenue beat on August 5, 2026, LLY rose from $1,115.68 to $1,220.66 over the next 30 trading sessions, for a +9.4% 30-day return. That supports the basic “buy revenue beats” idea, but it is still only one data point—not a statistically robust strategy yet.

For this test, the asset was Eli Lilly (LLY) with a revenue beat trigger, entering at the close on the earnings date and exiting 30 trading days later. The data window spanned from July 6, 2026, to August 5, 2026. LLY reported Q2 2026 revenue of $22.97 billion versus about $20.73 billion expected, a clear beat that immediately reacted in the stock. The market rewarded this topline strength even though parts of the report were mixed, including a non-GAAP EPS miss and meaningful one-time deal-related charges. This suggests the earnings narrative was constructive enough to overpower other negatives. From the August 5, 2026 close at $1,115.68 to the August 31, 2026 close at $1,220.66, LLY gained +9.4%. While the bullish takeaway is that LLY can deliver strong short-term moves on revenue beats driven by durable GLP-1 demand, the bearish caution is that this is a single-event backtest. A real edge likely requires testing at least 10–15 earnings events, separating results by guidance upgrades or cuts. For short-term, earnings-driven styles, LLY is a conditional yes, provided the beat comes with a constructive tone; if guidance or margins disappoint, the stock can still fade.

CEO Commentary

David A. Ricks, Lilly chair and CEO, emphasized that the company’s momentum continues with 48% revenue growth and raised full-year guidance. He highlighted that Lilly is building for the future through its next-generation weight-loss medicine, retatrutide, which now possesses a complete clinical data package supporting global registrations. Ricks also noted the addition of new assets via business development and the coming online of new manufacturing capacity. Concluding with an optimistic outlook, he stated that after 150 years, Lilly’s future has never been brighter, reflecting strong underlying business performance and strategic pipeline advancements.

Guidance

Lilly raised its 2026 full-year revenue guidance to a range of $85.0 billion to $87.0 billion, up from the previous range of $82.0 billion to $85.0 billion. The company increased its underlying non-GAAP EPS guidance by $2.78 at the midpoint due to strong business growth, resulting in an updated full-year non-GAAP EPS range of $35.50 to $36.50. This update reflects the offsetting impact of $3.03 in acquired in-process research and development charges from Q2 business development activities. Additionally, performance margin guidance was raised to 49.0% to 50.5%, while the tax rate guidance remained unchanged at 18% to 19%.

Additional News

Eli Lilly has significantly expanded its neuroscience capabilities through the acquisition of AtaiBeckley, a psychedelics specialist, in a deal valued at $2.8 billion. This strategic move aims to bolster Lilly's pipeline with novel treatments in mental health. Meanwhile, industry rivalry in the obesity sector intensifies as Novo Nordisk faces pressure despite reporting better-than-expected Q2 results, with its highly anticipated obesity pill sales falling short of Street estimates. Analysts note that Lilly's growth, underpinned by Zepbound and Mounjaro, has been "stupendous," with H1 2026 revenue already surpassing $42 billion. Furthermore, market sentiment remains cautious on AtaiBeckley, with a "Hold" rating assigned by Investing.com analysts, highlighting the integration risks associated with such high-profile M&A activity in the competitive biotech landscape.